BIOCRYST PHARMACEUTICA

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

05 апр 2024 09:45:07 Источник NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

04 апр 2024 15:51:53 Источник NetDania Notify

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 апр 2024 09:45:12 Источник NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 апр 2024 07:00:23 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

02 апр 2024 12:00:22 Источник NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

25 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

14 мар 2024 13:48:51 Источник NetDania Notify

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 мар 2024 07:01:47 Источник Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

26 фев 2024 07:00:05 Источник Nasdaq GlobeNewswire

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

23 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

21 фев 2024 16:01:58 Источник Nasdaq GlobeNewswire

BioCryst Launches ORLADEYO® (berotralstat) in Italy

19 фев 2024 07:54:52 Источник Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

12 фев 2024 07:00:53 Источник Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

05 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 фев 2024 07:00:48 Источник Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

05 янв 2024 16:01:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 янв 2024 16:01:59 Источник Nasdaq GlobeNewswire

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 07:00:50 Источник Nasdaq GlobeNewswire

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

19 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 дек 2023 16:01:42 Источник Nasdaq GlobeNewswire